A meta-analysis of impact of proton pump inhibitors on antiplatelet effect of clopidogrel

Cardiovascular Therapeutics

Volumn 30, Issue 5, 2012, Pages

  Chen, Mao ^a   Wei, Jia Fu ^a   Xu, Yuan Ning ^a   Liu, Xiao Jing ^a   Huang, De Jia ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Acute coronary syndrome; Antiplatelet; Clopidogrel; Proton pump inhibitor

Indexed keywords

CLOPIDOGREL; PROTON PUMP INHIBITOR;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; DRUG FATALITY; HEART INFARCTION; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STROKE;

ACUTE CORONARY SYNDROME; DATA INTERPRETATION, STATISTICAL; DRUG INTERACTIONS; ENDPOINT DETERMINATION; HUMANS; MYOCARDIAL INFARCTION; ODDS RATIO; PATIENT READMISSION; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE; TICLOPIDINE;

EID: 84866008342     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1755-5922.2011.00289.x     Document Type: Review

References (24)

1. King SB III, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2008;117:261-295.
2. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. Circulation 2008;118:1894-1909.
3. BJCardio editorial staff. EMEA warns of possible interaction between clopidogrel and PPIs. Br J Cardiol 2009;16:164.
4. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-260.
5. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. Am J Cardiol 2009;103:1339-1343.
6. Sibbing D, Morath T, Stegherr J, et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714-719.
7. O'Donoghue ML, Braunwald E, Antman EM, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials. Lancet 2009;374:989-997.
8. Ho PM, Maddox TM, Wang L, Fihn SD, Jesse RL, Peterson ED, Rumsfeld JS. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-944.
9. Stanek EJ, Aubert RE, Flockhart DA, et al. A national study of the effect of individual proton pump inhibitors on cardiovascular outcomes in patients treated with clopidogrel following coronary stenting: The Clopidogrel Medco Outcomes Study. Program and abstracts of the 32nd Annual SCAI Scientific Sessions, 2009, Las Vegas, Nevada.
10. European Medicines Agency. Public statement on possible interaction between clopidogrel and proton pump inhibitors. 2009. Available from: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Plavix/32895609en.pdf [Accessed 23 September 2009].
11. US Food and Drug Administration. Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix). Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafety-InformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm079520.htm [Accessed 23 September 2009].
12. Bhatt DL, Cryer BL, Contant CF, et al. Clopidogrel with or without Omeprazole in Coronary Artery Disease. N Engl J Med 2010;363:1909-1917.
13. Aubert RE, Teagarden JR, Xia F, et al. Proton pump inhibitors effect on Clopidogrel Effectiveness: The Clopidogrel Medco outcomes study. Circulation 2008;118:S815.
14. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 2007;116:2923-2932.
15. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015.
16. Dunn SP, Macaulay TE, Brennan DM, et al. Baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO Trial. Circulation 2008;118:S815.
17. Charlot M, Ahlehoff O, Norgaard ML, et al. Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use. A nationwide cohort study. Ann Intern Med 2010;153:378-386.
18. Ray WA, Murray KT, Griffin MR, et al. Outcomes with concurrent use of clopidogrel and proton-pump inhibitors. A cohort study. Ann Intern Med 2010;152:337-345.
19. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-718.
20. Lau WC, Waskell LA, Watkins PB, et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction. Circulation 2003;107:32-37.
21. Wienbergen H, Gitt AK, Schiele R, et al. Comparison of clinical benefits of clopidogrel therapy in patients with acute coronary syndromes taking atorvastatin versus other statin therapies. Am J Cardiol 2003;92:285-288.
22. Saw J, Steinhubl SR, Berger PB, et al. Lack of adverse clopidogrel atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 2003;108:921-924.
23. Gorchakova O, von Beckerath N, Gawaz M, et al. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting. Eur Heart J 2004;25:1898-1902.
24. Walker E, Hernandez AV, Kattan MW. Meta-analysis: Its strengths and limitations. Cleve Clin J Med 2008;75:431-439.